drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01165 | DB01206 | 1,539 | 37 | [
"DDInter1325",
"DDInter1086"
] | Ofloxacin | Lomustine | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | An alkylating agent of value against both hematologic malignancies and solid tumors. | Minor | 0 | [
[
[
1539,
23,
37
]
],
[
[
1539,
21,
28675
],
[
28675,
60,
37
]
],
[
[
1539,
40,
1176
],
[
1176,
23,
37
]
],
[
[
1539,
1,
956
],
[
956,
... | [
[
[
"Ofloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomustine"
]
],
[
[
"Ofloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Visual impairment"
],
[
"Visual impairment",
"{u} (Side Effe... | Ofloxacin (Compound) causes Visual impairment (Side Effect) and Visual impairment (Side Effect) is caused by Lomustine (Compound)
Ofloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Lomustine
Ofloxacin (Compound) resembles... |
DB00515 | DB01004 | 589 | 563 | [
"DDInter387",
"DDInter806"
] | Cisplatin | Ganciclovir | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Moderate | 1 | [
[
[
589,
24,
563
]
],
[
[
589,
24,
1295
],
[
1295,
1,
563
]
],
[
[
589,
24,
248
],
[
248,
40,
563
]
],
[
[
589,
21,
29169
],
[
29169,
... | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valaciclovir"
],
[
... | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Valaciclovir and Valaciclovir (Compound) resembles Ganciclovir (Compound)
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir (Compound) resembles Ganciclovir... |
DB00247 | DB06694 | 1,131 | 31 | [
"DDInter1194",
"DDInter1952"
] | Methysergide | Xylometazoline (nasal) | An ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize sero... | Xylometazoline is an alkylbenzene. | Major | 2 | [
[
[
1131,
25,
31
]
],
[
[
1131,
6,
10306
],
[
10306,
45,
31
]
],
[
[
1131,
40,
588
],
[
588,
25,
31
]
],
[
[
1131,
6,
10306
],
[
10306,
... | [
[
[
"Methysergide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Xylometazoline"
]
],
[
[
"Methysergide",
"{u} (Compound) binds {v} (Gene)",
"HTR1D"
],
[
"HTR1D",
"{u} (Gene) is bound by {v} (Compound)",
"X... | Methysergide may lead to a major life threatening interaction when taken with Xylometazoline
Methysergide (Compound) binds HTR1D (Gene) and HTR1D (Gene) is bound by Xylometazoline (Compound)
Methysergide (Compound) resembles Methylergometrine (Compound) and Methylergometrine may lead to a major life threatening interac... |
DB11248 | DB14491 | 1,193 | 428 | [
"DDInter1965",
"DDInter725"
] | Zinc gluconate | Ferrous fumarate | Zinc gluconate is a zinc salt of gluconic acid comprised of two gluconic acid molecules for each zinc cation (2+). Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA. It is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and wit... | Used in treatment of iron deficiency anemia. | Minor | 0 | [
[
[
1193,
23,
428
]
],
[
[
1193,
62,
1096
],
[
1096,
23,
428
]
],
[
[
1193,
63,
1008
],
[
1008,
24,
428
]
],
[
[
1193,
24,
133
],
[
133,
... | [
[
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mycophenolic acid... | Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Zinc gluconate may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00549 | DB00563 | 522 | 663 | [
"DDInter1955",
"DDInter1174"
] | Zafirlukast | Methotrexate | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Moderate | 1 | [
[
[
522,
24,
663
]
],
[
[
522,
6,
17404
],
[
17404,
45,
663
]
],
[
[
522,
21,
28681
],
[
28681,
60,
663
]
],
[
[
522,
24,
126
],
[
126,
... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]
],
[
[
"Zafirlukast",
"{u} (Compound) binds {v} (Gene)",
"ABCG2"
],
[
"ABCG2",
"{u} (Gene) is bound by {v} (Compound)... | Zafirlukast (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Methotrexate (Compound)
Zafirlukast (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Methotrexate (Compound)
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00004 | DB00446 | 669 | 597 | [
"DDInter499",
"DDInter351"
] | Denileukin diftitox | Chloramphenicol | A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system. | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Moderate | 1 | [
[
[
669,
24,
597
]
],
[
[
669,
24,
599
],
[
599,
24,
597
]
],
[
[
669,
24,
1362
],
[
1362,
63,
597
]
],
[
[
669,
25,
770
],
[
770,
6... | [
[
[
"Denileukin diftitox",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
]
],
[
[
"Denileukin diftitox",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alem... | Denileukin diftitox may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol
Denileukin diftitox may cause a moderate interaction that could exacerbate diseases when taken w... |
DB01177 | DB01182 | 77 | 371 | [
"DDInter904",
"DDInter1534"
] | Idarubicin | Propafenone | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Moderate | 1 | [
[
[
77,
24,
371
]
],
[
[
77,
63,
847
],
[
847,
1,
371
]
],
[
[
77,
63,
675
],
[
675,
40,
371
]
],
[
[
77,
63,
455
],
[
455,
24,
... | [
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propafenone"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atomoxetine"
],
[
... | Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Atomoxetine and Atomoxetine (Compound) resembles Propafenone (Compound)
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene (Compound) resembles Pro... |
DB00197 | DB15233 | 1,324 | 1,650 | [
"DDInter1881",
"DDInter142"
] | Troglitazone | Avapritinib | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Moderate | 1 | [
[
[
1324,
24,
1650
]
],
[
[
1324,
24,
1478
],
[
1478,
24,
1650
]
],
[
[
1324,
23,
1101
],
[
1101,
24,
1650
]
],
[
[
1324,
63,
966
],
[
966... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexar... |
DB00497 | DB00719 | 828 | 1,219 | [
"DDInter1366",
"DDInter149"
] | Oxycodone | Azatadine | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Moderate | 1 | [
[
[
828,
24,
1219
]
],
[
[
828,
63,
13
],
[
13,
24,
1219
]
],
[
[
828,
24,
830
],
[
830,
1,
1219
]
],
[
[
828,
6,
8374
],
[
8374,
45... | [
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
... | Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and... |
DB01234 | DB01344 | 1,220 | 1,231 | [
"DDInter513",
"DDInter1830"
] | Dexamethasone | Tolevamer | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Sodium polystyrene sulfonate is a medication used to treat abnormally high potassium levels. It may be taken orally or by rectum, as an enema, and functions as a potassium-binding resin in the intestines. It is also an effective topical microbicide and spermicide, inhibiting the genital transfection of, among others, H... | Moderate | 1 | [
[
[
1220,
24,
1231
]
],
[
[
1220,
23,
1114
],
[
1114,
63,
1231
]
],
[
[
1220,
24,
961
],
[
961,
63,
1231
]
],
[
[
1220,
1,
1486
],
[
1486,... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
]
],
[
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
... | Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Licorice and L... |
DB00420 | DB08871 | 508 | 36 | [
"DDInter1532",
"DDInter666"
] | Promazine | Eribulin | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
508,
24,
36
]
],
[
[
508,
24,
1424
],
[
1424,
24,
36
]
],
[
[
508,
1,
820
],
[
820,
24,
36
]
],
[
[
508,
40,
216
],
[
216,
24,
... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"Qu... | Promazine may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Promazine (Compound) resembles Alimemazine (Compound) and Alimemazine may cause a moderate interaction that could exacerb... |
DB00081 | DB00686 | 273 | 383 | [
"DDInter1838",
"DDInter1424"
] | Tositumomab | Pentosan polysulfate | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Pentosan polysulfate is a sulfated pentosyl polysaccharide with heparin-like properties. | Moderate | 1 | [
[
[
273,
24,
383
]
],
[
[
273,
25,
714
],
[
714,
63,
383
]
],
[
[
273,
64,
20
],
[
20,
24,
383
]
],
[
[
273,
25,
1061
],
[
1061,
24,... | [
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentosan polysulfate"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloprost"
],
[
"... | Tositumomab may lead to a major life threatening interaction when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate
Tositumomab may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a m... |
DB00357 | DB00582 | 1,051 | 1,622 | [
"DDInter71",
"DDInter1946"
] | Aminoglutethimide | Voriconazole | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Moderate | 1 | [
[
[
1051,
24,
1622
]
],
[
[
1051,
6,
8374
],
[
8374,
45,
1622
]
],
[
[
1051,
21,
28852
],
[
28852,
60,
1622
]
],
[
[
1051,
24,
466
],
[
46... | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
]
],
[
[
"Aminoglutethimide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by ... | Aminoglutethimide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Voriconazole (Compound)
Aminoglutethimide (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Voriconazole (Compound)
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when tak... |
DB01281 | DB06273 | 881 | 980 | [
"DDInter5",
"DDInter1824"
] | Abatacept | Tocilizumab | Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS mo... | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Major | 2 | [
[
[
881,
25,
980
]
],
[
[
881,
23,
1114
],
[
1114,
62,
980
]
],
[
[
881,
62,
1461
],
[
1461,
23,
980
]
],
[
[
881,
24,
949
],
[
949,
... | [
[
[
"Abatacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tocilizumab"
]
],
[
[
"Abatacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
"Zinc sulfat... | Abatacept may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Tocilizumab
Abatacept may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E ... |
DB00470 | DB01192 | 530 | 560 | [
"DDInter601",
"DDInter1372"
] | Dronabinol | Oxymorphone | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). O... | Moderate | 1 | [
[
[
530,
24,
560
]
],
[
[
530,
24,
828
],
[
828,
1,
560
]
],
[
[
530,
63,
421
],
[
421,
1,
560
]
],
[
[
530,
6,
8374
],
[
8374,
45,
... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxymorphone"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
],
[
... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) resembles Oxymorphone (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Oxymorphone (Comp... |
DB00398 | DB00978 | 79 | 739 | [
"DDInter1702",
"DDInter1084"
] | Sorafenib | Lomefloxacin | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Moderate | 1 | [
[
[
79,
24,
739
]
],
[
[
79,
25,
945
],
[
945,
40,
739
]
],
[
[
79,
24,
872
],
[
872,
40,
739
]
],
[
[
79,
64,
1176
],
[
1176,
1,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
]
],
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
],
[
"Sparflox... | Sorafenib may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Lomefloxacin (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Lomefloxacin (Compound)
Soraf... |
DB00647 | DB09278 | 675 | 852 | [
"DDInter528",
"DDInter24"
] | Dextropropoxyphene | Activated charcoal | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | Activated charcoal, or activated carbon, is an amorphous form of carbon prepared from incomplete combustion of carbonaceous organic matter. It is activated by an oxidizing gas flow at high temperature passed over its surface to make a fine network of pores, producing a material with large surface area and high affinity... | Moderate | 1 | [
[
[
675,
24,
852
]
],
[
[
675,
24,
1411
],
[
1411,
24,
852
]
],
[
[
675,
40,
1164
],
[
1164,
24,
852
]
],
[
[
675,
25,
1264
],
[
1264,
... | [
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Activated charcoal"
]
],
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tol... | Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Dextropropoxyphene (Compound) resembles Trimipramine (Compound) and Trimipramine may cause a m... |
DB00983 | DB01166 | 480 | 477 | [
"DDInter776",
"DDInter379"
] | Formoterol | Cilostazol | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
480,
24,
477
]
],
[
[
480,
6,
10215
],
[
10215,
45,
477
]
],
[
[
480,
21,
28919
],
[
28919,
60,
477
]
],
[
[
480,
63,
216
],
[
216,
... | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Formoterol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)... | Formoterol (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Cilostazol (Compound)
Formoterol (Compound) causes Arthritis (Side Effect) and Arthritis (Side Effect) is caused by Cilostazol (Compound)
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine an... |
DB01191 | DB01309 | 1,039 | 1,254 | [
"DDInter518",
"DDInter933"
] | Dexfenfluramine | Insulin glulisine | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Moderate | 1 | [
[
[
1039,
24,
1254
]
],
[
[
1039,
63,
1645
],
[
1645,
24,
1254
]
],
[
[
1039,
24,
266
],
[
266,
24,
1254
]
],
[
[
1039,
64,
73
],
[
73,
... | [
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"... | Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Bismut... |
DB00705 | DB05239 | 441 | 866 | [
"DDInter496",
"DDInter425"
] | Delavirdine | Cobimetinib | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Major | 2 | [
[
[
441,
25,
866
]
],
[
[
441,
25,
214
],
[
214,
63,
866
]
],
[
[
441,
63,
1051
],
[
1051,
24,
866
]
],
[
[
441,
24,
98
],
[
98,
63,... | [
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobimetinib"
]
],
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
... | Delavirdine may lead to a major life threatening interaction when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminogl... |
DB00035 | DB00939 | 1,314 | 1,338 | [
"DDInter507",
"DDInter1135"
] | Desmopressin | Meclofenamic acid | Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release... | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Moderate | 1 | [
[
[
1314,
24,
1338
]
],
[
[
1314,
23,
1479
],
[
1479,
63,
1338
]
],
[
[
1314,
6,
10522
],
[
10522,
45,
1338
]
],
[
[
1314,
21,
28900
],
[
... | [
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Desmopressin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acetylsalicylic ac... | Desmopressin may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Desmopressin (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Meclofenamic ... |
DB00569 | DB00812 | 553 | 998 | [
"DDInter775",
"DDInter1451"
] | Fondaparinux | Phenylbutazone | Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in he... | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | Major | 2 | [
[
[
553,
25,
998
]
],
[
[
553,
25,
804
],
[
804,
40,
998
]
],
[
[
553,
63,
305
],
[
305,
24,
998
]
],
[
[
553,
64,
1061
],
[
1061,
2... | [
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenylbutazone"
]
],
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sulfinpyrazone"
],
[
"Sulfinpyrazon... | Fondaparinux may lead to a major life threatening interaction when taken with Sulfinpyrazone and Sulfinpyrazone (Compound) resembles Phenylbutazone (Compound)
Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may ... |
DB11793 | DB15035 | 738 | 503 | [
"DDInter1297",
"DDInter1959"
] | Niraparib | Zanubrutinib | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long... | Moderate | 1 | [
[
[
738,
24,
503
]
],
[
[
738,
63,
868
],
[
868,
24,
503
]
],
[
[
738,
24,
1320
],
[
1320,
24,
503
]
],
[
[
738,
25,
676
],
[
676,
6... | [
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
... | Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagol... |
DB00374 | DB12364 | 1,061 | 1,421 | [
"DDInter1852",
"DDInter200"
] | Treprostinil | Betrixaban | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Major | 2 | [
[
[
1061,
25,
1421
]
],
[
[
1061,
23,
944
],
[
944,
62,
1421
]
],
[
[
1061,
23,
539
],
[
539,
23,
1421
]
],
[
[
1061,
63,
529
],
[
529,
... | [
[
[
"Treprostinil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Treprostinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile... | Treprostinil may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Betrixaban
Treprostinil may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may... |
DB00393 | DB09036 | 854 | 812 | [
"DDInter1295",
"DDInter1668"
] | Nimodipine | Siltuximab | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction ... | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | Moderate | 1 | [
[
[
854,
24,
812
]
],
[
[
854,
1,
1081
],
[
1081,
24,
812
]
],
[
[
854,
24,
259
],
[
259,
24,
812
]
],
[
[
854,
63,
1184
],
[
1184,
... | [
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
]
],
[
[
"Nimodipine",
"{u} (Compound) resembles {v} (Compound)",
"Nicardipine"
],
[
"Nicardipine",
"{u} may cause a moder... | Nimodipine (Compound) resembles Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that cou... |
DB00279 | DB00668 | 1,152 | 874 | [
"DDInter1074",
"DDInter652"
] | Liothyronine | Epinephrine | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmace... | Epinephrine, also known as _adrenaline_, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been avail... | Moderate | 1 | [
[
[
1152,
24,
874
]
],
[
[
1152,
24,
1636
],
[
1636,
1,
874
]
],
[
[
1152,
1,
1191
],
[
1191,
63,
874
]
],
[
[
1152,
7,
13230
],
[
13230,
... | [
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
],
... | Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine and Phenylephrine (Compound) resembles Epinephrine (Compound)
Liothyronine (Compound) resembles Levodopa (Compound) and Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Epin... |
DB00722 | DB08870 | 743 | 850 | [
"DDInter1079",
"DDInter228"
] | Lisinopril | Brentuximab vedotin | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldos... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
743,
24,
850
]
],
[
[
743,
63,
267
],
[
267,
24,
850
]
],
[
[
743,
24,
1344
],
[
1344,
63,
850
]
],
[
[
743,
1,
1058
],
[
1058,
... | [
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],... | Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozi... |
DB06772 | DB11988 | 310 | 270 | [
"DDInter259",
"DDInter1321"
] | Cabazitaxel | Ocrelizumab | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
310,
24,
270
]
],
[
[
310,
63,
1461
],
[
1461,
23,
270
]
],
[
[
310,
24,
1060
],
[
1060,
63,
270
]
],
[
[
310,
63,
134
],
[
134,
... | [
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and... |
DB00816 | DB01255 | 1,674 | 633 | [
"DDInter1346",
"DDInter1078"
] | Orciprenaline | Lisdexamfetamine | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved... | Moderate | 1 | [
[
[
1674,
24,
633
]
],
[
[
1674,
63,
551
],
[
551,
1,
633
]
],
[
[
1674,
63,
80
],
[
80,
40,
633
]
],
[
[
1674,
24,
1529
],
[
1529,
... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisdexamfetamine"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
... | Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine (Compound) resembles Lisdexamfetamine (Compound)
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine (Compound) resembles Lisdexam... |
DB01035 | DB09135 | 1,401 | 1,211 | [
"DDInter1524",
"DDInter967"
] | Procainamide | Ioxilan | A derivative of procaine with less CNS action. | Ioxilan is a tri-iodinated diagnostic contrast agent. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs. | Moderate | 1 | [
[
[
1401,
24,
1211
]
],
[
[
1401,
64,
485
],
[
485,
25,
1211
]
],
[
[
1401,
63,
1645
],
[
1645,
25,
1211
]
],
[
[
1401,
64,
485
],
[
485,
... | [
[
[
"Procainamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioxilan"
]
],
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentamidine"
],
[
"Pentamid... | Procainamide may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may lead to a major life threatening interaction when taken with Ioxilan
Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may lead to a major life... |
DB01149 | DB09268 | 851 | 1,662 | [
"DDInter1274",
"DDInter1464"
] | Nefazodone | Picosulfuric acid | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
851,
24,
1662
]
],
[
[
851,
25,
484
],
[
484,
63,
1662
]
],
[
[
851,
24,
1619
],
[
1619,
63,
1662
]
],
[
[
851,
25,
1618
],
[
1618,
... | [
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
],
[
"En... | Nefazodone may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may... |
DB00074 | DB09322 | 1,309 | 1,114 | [
"DDInter166",
"DDInter1966"
] | Basiliximab | Zinc sulfate | A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermenta... | Zinc sulfate is the inorganic compound with the formula ZnSO4 and historically known as "white vitriol". It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system. | Minor | 0 | [
[
[
1309,
23,
1114
]
],
[
[
1309,
24,
66
],
[
66,
23,
1114
]
],
[
[
1309,
64,
1057
],
[
1057,
23,
1114
]
],
[
[
1309,
63,
1184
],
[
1184,
... | [
[
[
"Basiliximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Basiliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
... | Basiliximab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Basiliximab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may caus... |
DB00261 | DB03404 | 702 | 765 | [
"DDInter93",
"DDInter855"
] | Anagrelide | Hemin | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Hemin (trade name Panhematin) is an iron-containing porphyrin. More specifically, it is protoporphyrin IX containing a ferric iron ion (heme B) with a chloride ligand. | Moderate | 1 | [
[
[
702,
24,
765
]
],
[
[
702,
25,
840
],
[
840,
63,
765
]
],
[
[
702,
25,
291
],
[
291,
24,
765
]
],
[
[
702,
63,
1018
],
[
1018,
2... | [
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
],
[
"Vorapaxar",
... | Anagrelide may lead to a major life threatening interaction when taken with Vorapaxar and Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Hemin
Anagrelide may lead to a major life threatening interaction when taken with Argatroban and Argatroban may cause a moderate interaction... |
DB05294 | DB11718 | 1,069 | 927 | [
"DDInter1917",
"DDInter640"
] | Vandetanib | Encorafenib | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Major | 2 | [
[
[
1069,
25,
927
]
],
[
[
1069,
62,
112
],
[
112,
23,
927
]
],
[
[
1069,
24,
720
],
[
720,
24,
927
]
],
[
[
1069,
64,
216
],
[
216,
... | [
[
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Vandetanib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Vandetanib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and Mi... |
DB00598 | DB09333 | 1,523 | 278 | [
"DDInter1013",
"DDInter963"
] | Labetalol | Iopodic acid | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Iopodic acid, also known by the name of ipodate, is classified as a cholecystographic agent formed by a weak organic acid that contains a tri-iodinated benzene ring with iodine at positions 2, 4 and 6. Due to its particular structure, it presents a high degree of lipid solubility and a radiopaque property. It was devel... | Moderate | 1 | [
[
[
1523,
24,
278
]
],
[
[
1523,
63,
1648
],
[
1648,
24,
278
]
],
[
[
1523,
24,
1527
],
[
1527,
24,
278
]
],
[
[
1523,
63,
1648
],
[
1648,... | [
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
... | Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid and... |
DB04845 | DB11901 | 309 | 913 | [
"DDInter1001",
"DDInter107"
] | Ixabepilone | Apalutamide | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
309,
24,
913
]
],
[
[
309,
63,
112
],
[
112,
23,
913
]
],
[
[
309,
24,
110
],
[
110,
62,
913
]
],
[
[
309,
63,
600
],
[
600,
24,... | [
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab ve... |
DB12010 | DB12893 | 214 | 586 | [
"DDInter785",
"DDInter1629"
] | Fostamatinib | Sacituzumab govitecan | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA. Recently, fosta... | Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents. Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment. One such ADC is sacituzumab goviteca... | Major | 2 | [
[
[
214,
25,
586
]
],
[
[
214,
63,
869
],
[
869,
24,
586
]
],
[
[
214,
64,
384
],
[
384,
24,
586
]
],
[
[
214,
24,
1017
],
[
1017,
2... | [
[
[
"Fostamatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sacituzumab govitecan"
]
],
[
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
... | Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Sacituzumab govitecan
Fostamatinib may lead to a major life threatening interaction when taken with Idelalisib and Idelalis... |
DB04835 | DB08865 | 1,655 | 1,593 | [
"DDInter1125",
"DDInter448"
] | Maraviroc | Crizotinib | Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Mara... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
1655,
24,
1593
]
],
[
[
1655,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
1655,
7,
6952
],
[
6952,
46,
1593
]
],
[
[
1655,
21,
30045
],
[
300... | [
[
[
"Maraviroc",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Maraviroc",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Maraviroc (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Maraviroc (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Crizotinib (Compound)
Maraviroc (Compound) causes Dizziness postural (Side Effect) and Dizziness postural (Side Effect) is caused by Crizotinib ... |
DB00188 | DB12887 | 168 | 1,598 | [
"DDInter222",
"DDInter1750"
] | Bortezomib | Tazemetostat | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Minor | 0 | [
[
[
168,
23,
1598
]
],
[
[
168,
23,
985
],
[
985,
24,
1598
]
],
[
[
168,
24,
310
],
[
310,
24,
1598
]
],
[
[
168,
23,
982
],
[
982,
... | [
[
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tazemetostat"
]
],
[
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osimertinib"
],
[
... | Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cab... |
DB00390 | DB00397 | 1,252 | 1,466 | [
"DDInter554",
"DDInter1458"
] | Digoxin | Phenylpropanolamine | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | Moderate | 1 | [
[
[
1252,
24,
1466
]
],
[
[
1252,
18,
7744
],
[
7744,
57,
1466
]
],
[
[
1252,
21,
28929
],
[
28929,
60,
1466
]
],
[
[
1252,
23,
1662
],
[
... | [
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylpropanolamine"
]
],
[
[
"Digoxin",
"{u} (Compound) downregulates {v} (Gene)",
"PRR7"
],
[
"PRR7",
"{u} (Gene) is downregulated by {... | Digoxin (Compound) downregulates PRR7 (Gene) and PRR7 (Gene) is downregulated by Phenylpropanolamine (Compound)
Digoxin (Compound) causes Confusional state (Side Effect) and Confusional state (Side Effect) is caused by Phenylpropanolamine (Compound)
Digoxin may cause a minor interaction that can limit clinical effects ... |
DB00424 | DB00502 | 19 | 1,300 | [
"DDInter896",
"DDInter853"
] | Hyoscyamine | Haloperidol | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Moderate | 1 | [
[
[
19,
24,
1300
]
],
[
[
19,
24,
543
],
[
543,
63,
1300
]
],
[
[
19,
21,
28835
],
[
28835,
60,
1300
]
],
[
[
19,
74,
1089
],
[
1089,
... | [
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Haloperidol"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[... | Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Haloperidol
Hyoscyamine (Compound) causes Hyperglycaemia (Side Effect) and Hyperglycaemia (Side Effect) is caused by Halop... |
DB00685 | DB00704 | 1,299 | 267 | [
"DDInter1887",
"DDInter1263"
] | Trovafloxacin | Naltrexone | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Moderate | 1 | [
[
[
1299,
24,
267
]
],
[
[
1299,
63,
475
],
[
475,
25,
267
]
],
[
[
1299,
21,
28695
],
[
28695,
60,
267
]
],
[
[
1299,
24,
850
],
[
850,
... | [
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
... | Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Naltrexone
Trovafloxacin (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Naltrexone (Compound)
Trovafloxac... |
DB11703 | DB11952 | 405 | 800 | [
"DDInter9",
"DDInter612"
] | Acalabrutinib | Duvelisib | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Major | 2 | [
[
[
405,
25,
800
]
],
[
[
405,
63,
222
],
[
222,
23,
800
]
],
[
[
405,
24,
1476
],
[
1476,
63,
800
]
],
[
[
405,
63,
440
],
[
440,
2... | [
[
[
"Acalabrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duvelisib"
]
],
[
[
"Acalabrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibu... | Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Duvelisib
Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and B... |
DB00762 | DB11642 | 613 | 938 | [
"DDInter973",
"DDInter1480"
] | Irinotecan | Pitolisant | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnag... | Moderate | 1 | [
[
[
613,
24,
938
]
],
[
[
613,
25,
760
],
[
760,
24,
938
]
],
[
[
613,
24,
28
],
[
28,
24,
938
]
],
[
[
613,
63,
600
],
[
600,
24,
... | [
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Irinotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
],
[
"Cobicistat... | Irinotecan may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl may cause a ... |
DB12500 | DB14881 | 283 | 180 | [
"DDInter714",
"DDInter1329"
] | Fedratinib | Oliceridine | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Major | 2 | [
[
[
283,
25,
180
]
],
[
[
283,
63,
401
],
[
401,
24,
180
]
],
[
[
283,
64,
484
],
[
484,
24,
180
]
],
[
[
283,
24,
159
],
[
159,
24,... | [
[
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
]
],
[
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Prometh... | Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Fedratinib may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may... |
DB06589 | DB08880 | 1,250 | 1,510 | [
"DDInter1400",
"DDInter1771"
] | Pazopanib | Teriflunomide | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
1250,
25,
1510
]
],
[
[
1250,
24,
129
],
[
129,
63,
1510
]
],
[
[
1250,
24,
1136
],
[
1136,
24,
1510
]
],
[
[
1250,
63,
563
],
[
563,
... | [
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalut... | Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and De... |
DB05273 | DB09052 | 507 | 250 | [
"DDInter1638",
"DDInter220"
] | Samarium (153Sm) lexidronam | Blinatumomab | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium ... | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostl... | Major | 2 | [
[
[
507,
25,
250
]
],
[
[
507,
25,
1362
],
[
1362,
63,
250
]
],
[
[
507,
64,
599
],
[
599,
24,
250
]
],
[
[
507,
25,
850
],
[
850,
2... | [
[
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Blinatumomab"
]
],
[
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
],
... | Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Alemtuzumab and Ale... |
DB00035 | DB00749 | 1,314 | 59 | [
"DDInter507",
"DDInter699"
] | Desmopressin | Etodolac | Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release... | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Moderate | 1 | [
[
[
1314,
24,
59
]
],
[
[
1314,
6,
10522
],
[
10522,
45,
59
]
],
[
[
1314,
21,
29187
],
[
29187,
60,
59
]
],
[
[
1314,
40,
16
],
[
16,
... | [
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etodolac"
]
],
[
[
"Desmopressin",
"{u} (Compound) binds {v} (Gene)",
"PTGS1"
],
[
"PTGS1",
"{u} (Gene) is bound by {v} (Compound)",... | Desmopressin (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Etodolac (Compound)
Desmopressin (Compound) causes Rhinitis (Side Effect) and Rhinitis (Side Effect) is caused by Etodolac (Compound)
Desmopressin (Compound) resembles Linaclotide (Compound) and Linaclotide may cause a minor interaction that can li... |
DB01203 | DB01222 | 699 | 617 | [
"DDInter1255",
"DDInter246"
] | Nadolol | Budesonide | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adv... | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Moderate | 1 | [
[
[
699,
24,
617
]
],
[
[
699,
63,
251
],
[
251,
1,
617
]
],
[
[
699,
24,
1220
],
[
1220,
1,
617
]
],
[
[
699,
18,
20113
],
[
20113,
... | [
[
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
... | Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Budesonide (Compound)
Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Budesonide (Comp... |
DB00635 | DB11113 | 1,573 | 657 | [
"DDInter1515",
"DDInter307"
] | Prednisone | Castor oil | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
1573,
24,
657
]
],
[
[
1573,
24,
1326
],
[
1326,
24,
657
]
],
[
[
1573,
1,
891
],
[
891,
24,
657
]
],
[
[
1573,
25,
739
],
[
739,
... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenamide"
],
[... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Diclofenamide and Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Prednisone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction ... |
DB00738 | DB01224 | 485 | 623 | [
"DDInter1420",
"DDInter1553"
] | Pentamidine | Quetiapine | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Moderate | 1 | [
[
[
485,
24,
623
]
],
[
[
485,
63,
827
],
[
827,
1,
623
]
],
[
[
485,
64,
695
],
[
695,
1,
623
]
],
[
[
485,
24,
1178
],
[
1178,
1,
... | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trazodone"
],
[
... | Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Quetiapine (Compound)
Pentamidine may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) resembles Quetiapine (Compound)
Pentamidine may c... |
DB01138 | DB12941 | 804 | 466 | [
"DDInter1726",
"DDInter481"
] | Sulfinpyrazone | Darolutamide | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Moderate | 1 | [
[
[
804,
24,
466
]
],
[
[
804,
24,
351
],
[
351,
23,
466
]
],
[
[
804,
63,
723
],
[
723,
23,
466
]
],
[
[
804,
24,
159
],
[
159,
62,... | [
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]... | Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant an... |
DB00308 | DB13074 | 347 | 877 | [
"DDInter901",
"DDInter1110"
] | Ibutilide | Macimorelin | Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
347,
25,
877
]
],
[
[
347,
23,
112
],
[
112,
23,
877
]
],
[
[
347,
25,
913
],
[
913,
24,
877
]
],
[
[
347,
24,
770
],
[
770,
24,... | [
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Ibutilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidaz... | Ibutilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Ibutilide may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cau... |
DB00827 | DB01261 | 646 | 170 | [
"DDInter383",
"DDInter1679"
] | Cinoxacin | Sitagliptin | Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections. | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Moderate | 1 | [
[
[
646,
24,
170
]
],
[
[
646,
21,
28921
],
[
28921,
60,
170
]
],
[
[
646,
24,
52
],
[
52,
62,
170
]
],
[
[
646,
64,
1179
],
[
1179,
... | [
[
[
"Cinoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Cinoxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is cause... | Cinoxacin (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Sitagliptin (Compound)
Cinoxacin may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a minor interaction that can limit clinical effects when taken with Sitaglip... |
DB00872 | DB11703 | 1,080 | 405 | [
"DDInter438",
"DDInter9"
] | Conivaptan | Acalabrutinib | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
1080,
25,
405
]
],
[
[
1080,
63,
1324
],
[
1324,
24,
405
]
],
[
[
1080,
62,
1101
],
[
1101,
24,
405
]
],
[
[
1080,
25,
951
],
[
951,
... | [
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Trogl... | Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Conivaptan may cause a minor interaction that can limit clinical effects when taken with Bexarotene and B... |
DB00434 | DB04843 | 13 | 1,511 | [
"DDInter459",
"DDInter1149"
] | Cyproheptadine | Mepenzolate | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
13,
24,
1511
]
],
[
[
13,
25,
675
],
[
675,
24,
1511
]
],
[
[
13,
24,
537
],
[
537,
24,
1511
]
],
[
[
13,
63,
352
],
[
352,
24,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Cyproheptadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
[
... | Cyproheptadine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine a... |
DB01381 | DB11901 | 958 | 913 | [
"DDInter819",
"DDInter107"
] | Ginkgo biloba | Apalutamide | _Ginkgo biloba_ extract contains a group of terpene lactones (notably, ginkgolides and diterpenes) and ginkgo flavone glycosides (notably, ginkgetin, bilobetin, and sciadopitysin) that have antioxidant and vasoactive properties. Most of the studies that investigate the effect of _ginkgo biloba_ use the standardized ext... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
958,
24,
913
]
],
[
[
958,
63,
608
],
[
608,
23,
913
]
],
[
[
958,
63,
401
],
[
401,
24,
913
]
],
[
[
958,
24,
1421
],
[
1421,
6... | [
[
[
"Ginkgo biloba",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Ginkgo biloba",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
... | Ginkgo biloba may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Ginkgo biloba may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and P... |
DB00465 | DB08816 | 886 | 578 | [
"DDInter1010",
"DDInter1802"
] | Ketorolac | Ticagrelor | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, men... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
886,
24,
578
]
],
[
[
886,
21,
28646
],
[
28646,
60,
578
]
],
[
[
886,
63,
1578
],
[
1578,
24,
578
]
],
[
[
886,
76,
1172
],
[
1172,
... | [
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Ketorolac",
"{u} (Compound) causes {v} (Side Effect)",
"Unspecified disorder of skin and subcutaneous tissue"
],
[
"Uns... | Ketorolac (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Ticagrelor (Compound)
Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin and Lepirudin may c... |
DB00163 | DB01229 | 1,461 | 973 | [
"DDInter1943",
"DDInter1377"
] | Vitamin E | Paclitaxel | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Moderate | 1 | [
[
[
1461,
24,
973
]
],
[
[
1461,
24,
310
],
[
310,
63,
973
]
],
[
[
1461,
6,
7432
],
[
7432,
45,
973
]
],
[
[
1461,
18,
10496
],
[
10496,
... | [
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
... | Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Vitamin E (Compound) binds NR1I2 (Gene) and NR1I2 (Gene) is bound by Paclitaxel (Compound)
Vitamin E (Compound)... |
DB06077 | DB09043 | 879 | 135 | [
"DDInter1102",
"DDInter36"
] | Lumateperone | Albiglutide | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumatepero... | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
879,
24,
135
]
],
[
[
879,
63,
1647
],
[
1647,
23,
135
]
],
[
[
879,
63,
176
],
[
176,
24,
135
]
],
[
[
879,
25,
1476
],
[
1476,
... | [
[
[
"Lumateperone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Lumateperone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
[... | Lumateperone may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Lumateperone may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and I... |
DB00975 | DB01404 | 1,317 | 757 | [
"DDInter573",
"DDInter820"
] | Dipyridamole | Ginseng | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Ginseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties. Ginseng is also known to contain phytoestrogens. | Moderate | 1 | [
[
[
1317,
24,
757
]
],
[
[
1317,
63,
25
],
[
25,
24,
757
]
],
[
[
1317,
24,
578
],
[
578,
63,
757
]
],
[
[
1317,
64,
553
],
[
553,
2... | [
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anistreplase"
],
[... | Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Anistreplase and Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and T... |
DB11642 | DB11921 | 938 | 1,019 | [
"DDInter1480",
"DDInter492"
] | Pitolisant | Deflazacort | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnag... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
938,
24,
1019
]
],
[
[
938,
24,
1619
],
[
1619,
63,
1019
]
],
[
[
938,
63,
355
],
[
355,
24,
1019
]
],
[
[
938,
25,
877
],
[
877,
... | [
[
[
"Pitolisant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Pitolisant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
... | Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulos... |
DB00991 | DB06779 | 97 | 365 | [
"DDInter1358",
"DDInter470"
] | Oxaprozin | Dalteparin | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the r... | Major | 2 | [
[
[
97,
25,
365
]
],
[
[
97,
63,
305
],
[
305,
24,
365
]
],
[
[
97,
24,
1039
],
[
1039,
24,
365
]
],
[
[
97,
24,
738
],
[
738,
63,
... | [
[
[
"Oxaprozin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
]
],
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
... | Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin
Oxaprozin may cause a moderate interaction that could exacerbate diseases w... |
DB00927 | DB08868 | 1,559 | 1,011 | [
"DDInter712",
"DDInter737"
] | Famotidine | Fingolimod | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Moderate | 1 | [
[
[
1559,
24,
1011
]
],
[
[
1559,
21,
28859
],
[
28859,
60,
1011
]
],
[
[
1559,
23,
1247
],
[
1247,
23,
1011
]
],
[
[
1559,
62,
112
],
[
1... | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Famotidine",
"{u} (Compound) causes {v} (Side Effect)",
"Atrioventricular block"
],
[
"Atrioventricular block",
... | Famotidine (Compound) causes Atrioventricular block (Side Effect) and Atrioventricular block (Side Effect) is caused by Fingolimod (Compound)
Famotidine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinic... |
DB00526 | DB04855 | 1,555 | 540 | [
"DDInter1355",
"DDInter602"
] | Oxaliplatin | Dronedarone | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Major | 2 | [
[
[
1555,
25,
540
]
],
[
[
1555,
64,
347
],
[
347,
40,
540
]
],
[
[
1555,
25,
33
],
[
33,
40,
540
]
],
[
[
1555,
24,
112
],
[
112,
2... | [
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibutilide"
],
[
"Ibutilide",
"{u} ... | Oxaliplatin may lead to a major life threatening interaction when taken with Ibutilide and Ibutilide (Compound) resembles Dronedarone (Compound)
Oxaliplatin may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone (Compound) resembles Dronedarone (Compound)
Oxaliplatin may cause a mode... |
DB08912 | DB11703 | 1,040 | 405 | [
"DDInter462",
"DDInter9"
] | Dabrafenib | Acalabrutinib | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
1040,
24,
405
]
],
[
[
1040,
24,
1384
],
[
1384,
24,
405
]
],
[
[
1040,
63,
690
],
[
690,
24,
405
]
],
[
[
1040,
62,
1101
],
[
1101,
... | [
[
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
],
[... | Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate and Magaldrate may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifa... |
DB00489 | DB01142 | 17 | 1,264 | [
"DDInter1704",
"DDInter593"
] | Sotalol | Doxepin | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Major | 2 | [
[
[
17,
25,
1264
]
],
[
[
17,
25,
401
],
[
401,
24,
1264
]
],
[
[
17,
6,
3958
],
[
3958,
45,
1264
]
],
[
[
17,
21,
28954
],
[
28954,
... | [
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
]
],
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may ca... | Sotalol may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Sotalol (Compound) binds KCNH2 (Gene) and KCNH2 (Gene) is bound by Doxepin (Compound)
Sotalol (Compound) causes Cramp muscle (Sid... |
DB01045 | DB11691 | 463 | 1,499 | [
"DDInter1590",
"DDInter1258"
] | Rifampicin | Naldemedine | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opi... | Major | 2 | [
[
[
463,
25,
1499
]
],
[
[
463,
63,
723
],
[
723,
24,
1499
]
],
[
[
463,
64,
1419
],
[
1419,
24,
1499
]
],
[
[
463,
25,
1670
],
[
1670,
... | [
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naldemedine"
]
],
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitan... | Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Rifampicin may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a m... |
DB00619 | DB09122 | 1,419 | 1,613 | [
"DDInter909",
"DDInter1409"
] | Imatinib | Peginterferon beta-1a | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
1419,
24,
1613
]
],
[
[
1419,
24,
671
],
[
671,
24,
1613
]
],
[
[
1419,
23,
1627
],
[
1627,
24,
1613
]
],
[
[
1419,
63,
152
],
[
152,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Imatinib may cause a minor interaction that can limit clinical effects when taken with Cannabidiol an... |
DB00055 | DB06603 | 834 | 39 | [
"DDInter605",
"DDInter1387"
] | Drotrecogin alfa | Panobinostat | Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated th... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
834,
25,
39
]
],
[
[
834,
25,
578
],
[
578,
63,
39
]
],
[
[
834,
24,
383
],
[
383,
24,
39
]
],
[
[
834,
25,
998
],
[
998,
24,
... | [
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor"... | Drotrecogin alfa may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate a... |
DB00188 | DB08882 | 168 | 1,281 | [
"DDInter222",
"DDInter1070"
] | Bortezomib | Linagliptin | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
168,
24,
1281
]
],
[
[
168,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
168,
6,
8374
],
[
8374,
45,
1281
]
],
[
[
168,
21,
28966
],
[
28966,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
[
... | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Bortezomib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Linagliptin (Compound)
Bortezomib (Compound) causes Upper respiratory tract infection (... |
DB06209 | DB06605 | 256 | 1,409 | [
"DDInter1508",
"DDInter108"
] | Prasugrel | Apixaban | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Major | 2 | [
[
[
256,
25,
1409
]
],
[
[
256,
6,
10215
],
[
10215,
45,
1409
]
],
[
[
256,
21,
28787
],
[
28787,
60,
1409
]
],
[
[
256,
23,
539
],
[
539,... | [
[
[
"Prasugrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Prasugrel",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Apixaban"... | Prasugrel (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Apixaban (Compound)
Prasugrel (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Apixaban (Compound)
Prasugrel may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum ma... |
DB01168 | DB09237 | 1,053 | 1,586 | [
"DDInter1526",
"DDInter1045"
] | Procarbazine | Levamlodipine | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlod... | Moderate | 1 | [
[
[
1053,
24,
1586
]
],
[
[
1053,
63,
1648
],
[
1648,
24,
1586
]
],
[
[
1053,
64,
593
],
[
593,
24,
1586
]
],
[
[
1053,
25,
908
],
[
908,
... | [
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
... | Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Procarbazine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may... |
DB05294 | DB08864 | 1,069 | 786 | [
"DDInter1917",
"DDInter1595"
] | Vandetanib | Rilpivirine | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Major | 2 | [
[
[
1069,
25,
786
]
],
[
[
1069,
6,
8374
],
[
8374,
45,
786
]
],
[
[
1069,
21,
29343
],
[
29343,
60,
786
]
],
[
[
1069,
62,
112
],
[
112,
... | [
[
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilpivirine"
]
],
[
[
"Vandetanib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Rilpiv... | Vandetanib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rilpivirine (Compound)
Vandetanib (Compound) causes Blood creatinine increased (Side Effect) and Blood creatinine increased (Side Effect) is caused by Rilpivirine (Compound)
Vandetanib may cause a minor interaction that can limit clinical effects w... |
DB00015 | DB00758 | 582 | 1,347 | [
"DDInter1585",
"DDInter413"
] | Reteplase | Clopidogrel | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids p... | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Moderate | 1 | [
[
[
582,
24,
1347
]
],
[
[
582,
24,
1018
],
[
1018,
25,
1347
]
],
[
[
582,
23,
539
],
[
539,
62,
1347
]
],
[
[
582,
24,
958
],
[
958,
... | [
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
... | Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may lead to a major life threatening interaction when taken with Clopidogrel
Reteplase may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a min... |
DB00195 | DB00225 | 726 | 457 | [
"DDInter198",
"DDInter794"
] | Betaxolol (ophthalmic) | Gadodiamide | Betaxolol is a propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydoxy is substituted by a 4-[2-(cyclopropylmethoxy)ethyl]phenyl group and one of the hydrogens attached to the amino group is substituted by isopropyl. It is a selective beta1-receptor blocker and is used in the treatment... | Gadodiamide is a linear, non-ionic gadolinium-based contrast agent (GBCA) that is used in magnetic resonance imaging (MRI) procedures to assist in the visualization of blood vessels.[A263086,A263091] GBCAs constitute the largest group of MR agents, and they are thought to be safer than nonionic iodinated contrast agent... | Moderate | 1 | [
[
[
726,
24,
457
]
],
[
[
726,
24,
1106
],
[
1106,
1,
457
]
],
[
[
726,
24,
796
],
[
796,
40,
457
]
],
[
[
726,
21,
28845
],
[
28845,
... | [
[
[
"Betaxolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadodiamide"
]
],
[
[
"Betaxolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadofosveset trisodium"
... | Betaxolol may cause a moderate interaction that could exacerbate diseases when taken with Gadodiamide
Betaxolol may cause a moderate interaction that could exacerbate diseases when taken with Gadofosveset trisodium and Gadofosveset trisodium (Compound) resembles Gadodiamide (Compound)
Betaxolol may cause a moderate int... |
DB00297 | DB12130 | 606 | 1,017 | [
"DDInter249",
"DDInter1094"
] | Bupivacaine | Lorlatinib | Bupivacaine is a widely used local anesthetic agent. | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
606,
24,
1017
]
],
[
[
606,
40,
608
],
[
608,
23,
1017
]
],
[
[
606,
24,
629
],
[
629,
24,
1017
]
],
[
[
606,
40,
608
],
[
608,
... | [
[
[
"Bupivacaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Bupivacaine",
"{u} (Compound) resembles {v} (Compound)",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor i... | Bupivacaine (Compound) resembles Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Bupivacaine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exa... |
DB00877 | DB01100 | 629 | 1,568 | [
"DDInter1678",
"DDInter1470"
] | Sirolimus | Pimozide | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Moderate | 1 | [
[
[
629,
24,
1568
]
],
[
[
629,
24,
1149
],
[
1149,
1,
1568
]
],
[
[
629,
63,
1557
],
[
1557,
25,
1568
]
],
[
[
629,
6,
7524
],
[
7524,
... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pimozide"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ezetimibe"
],
[
"... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Ezetimibe and Ezetimibe (Compound) resembles Pimozide (Compound)
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Astemizole and Astemizole may lead to a major life threatening interaction ... |
DB06717 | DB15091 | 875 | 676 | [
"DDInter778",
"DDInter1901"
] | Fosaprepitant | Upadacitinib | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Moderate | 1 | [
[
[
875,
24,
676
]
],
[
[
875,
24,
283
],
[
283,
24,
676
]
],
[
[
875,
63,
600
],
[
600,
24,
676
]
],
[
[
875,
40,
723
],
[
723,
24,... | [
[
[
"Fosaprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Fosaprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
... | Fosaprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Fosaprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole a... |
DB01232 | DB09079 | 1,327 | 1,496 | [
"DDInter1640",
"DDInter1296"
] | Saquinavir | Nintedanib | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis trea... | Moderate | 1 | [
[
[
1327,
24,
1496
]
],
[
[
1327,
64,
609
],
[
609,
24,
1496
]
],
[
[
1327,
25,
840
],
[
840,
24,
1496
]
],
[
[
1327,
25,
913
],
[
913,
... | [
[
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarit... | Saquinavir may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Saquinavir may lead to a major life threatening interaction when taken with Vorapaxar and Vorapaxar may cause a moderat... |
DB00196 | DB08816 | 600 | 578 | [
"DDInter743",
"DDInter1802"
] | Fluconazole | Ticagrelor | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
600,
24,
578
]
],
[
[
600,
6,
4973
],
[
4973,
45,
578
]
],
[
[
600,
54,
19146
],
[
19146,
15,
578
]
],
[
[
600,
21,
28646
],
[
28646,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Fluconazole",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",... | Fluconazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ticagrelor (Compound)
Fluconazole (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Ticagrelor (Compound)
Fluconazole (Compound) causes Unspecified disord... |
DB00776 | DB12364 | 1,335 | 1,421 | [
"DDInter1360",
"DDInter200"
] | Oxcarbazepine | Betrixaban | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Moderate | 1 | [
[
[
1335,
24,
1421
]
],
[
[
1335,
24,
1513
],
[
1513,
24,
1421
]
],
[
[
1335,
63,
888
],
[
888,
24,
1421
]
],
[
[
1335,
40,
1236
],
[
1236... | [
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apremilast"
],
... | Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Apremilast and Apremilast may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and T... |
DB00598 | DB01234 | 1,523 | 1,220 | [
"DDInter1013",
"DDInter513"
] | Labetalol | Dexamethasone | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
1523,
24,
1220
]
],
[
[
1523,
24,
870
],
[
870,
1,
1220
]
],
[
[
1523,
24,
175
],
[
175,
40,
1220
]
],
[
[
1523,
63,
251
],
[
251,
... | [
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
... | Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Dexam... |
DB00622 | DB00653 | 1,081 | 544 | [
"DDInter1287",
"DDInter1120"
] | Nicardipine | Magnesium sulfate | A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [Pub... | A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions... | Moderate | 1 | [
[
[
1081,
24,
544
]
],
[
[
1081,
6,
2044
],
[
2044,
45,
544
]
],
[
[
1081,
21,
28717
],
[
28717,
60,
544
]
],
[
[
1081,
40,
854
],
[
854,
... | [
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfate"
]
],
[
[
"Nicardipine",
"{u} (Compound) binds {v} (Gene)",
"CACNB2"
],
[
"CACNB2",
"{u} (Gene) is bound by {v} (Co... | Nicardipine (Compound) binds CACNB2 (Gene) and CACNB2 (Gene) is bound by Magnesium sulfate (Compound)
Nicardipine (Compound) causes Flushing (Side Effect) and Flushing (Side Effect) is caused by Magnesium sulfate (Compound)
Nicardipine (Compound) resembles Nimodipine (Compound) and Nimodipine may cause a moderate inter... |
DB06772 | DB08827 | 310 | 990 | [
"DDInter259",
"DDInter1085"
] | Cabazitaxel | Lomitapide | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Moderate | 1 | [
[
[
310,
24,
990
]
],
[
[
310,
63,
1080
],
[
1080,
1,
990
]
],
[
[
310,
6,
8374
],
[
8374,
45,
990
]
],
[
[
310,
21,
28701
],
[
28701,
... | [
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conivaptan"
],
[
... | Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Conivaptan and Conivaptan (Compound) resembles Lomitapide (Compound)
Cabazitaxel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lomitapide (Compound)
Cabazitaxel (Compound) causes Discomfort (Side Effect) and Disco... |
DB00341 | DB00633 | 1,242 | 614 | [
"DDInter343",
"DDInter520"
] | Cetirizine | Dexmedetomidine | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine. | Moderate | 1 | [
[
[
1242,
24,
614
]
],
[
[
1242,
21,
28900
],
[
28900,
60,
614
]
],
[
[
1242,
24,
222
],
[
222,
63,
614
]
],
[
[
1242,
63,
1648
],
[
1648,... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexmedetomidine"
]
],
[
[
"Cetirizine",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side ... | Cetirizine (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dexmedetomidine (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when t... |
DB01015 | DB08875 | 1,247 | 1,618 | [
"DDInter1724",
"DDInter262"
] | Sulfamethoxazole | Cabozantinib | Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps i... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Minor | 0 | [
[
[
1247,
23,
1618
]
],
[
[
1247,
62,
112
],
[
112,
23,
1618
]
],
[
[
1247,
24,
384
],
[
384,
63,
1618
]
],
[
[
1247,
24,
850
],
[
850,
... | [
[
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cabozantinib"
]
],
[
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
... | Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Idela... |
DB00673 | DB06603 | 723 | 39 | [
"DDInter112",
"DDInter1387"
] | Aprepitant | Panobinostat | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Moderate | 1 | [
[
[
723,
24,
39
]
],
[
[
723,
23,
479
],
[
479,
23,
39
]
],
[
[
723,
24,
211
],
[
211,
23,
39
]
],
[
[
723,
23,
1627
],
[
1627,
63,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
... | Aprepitant may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodi... |
DB09570 | DB10795 | 1,480 | 221 | [
"DDInter1002",
"DDInter1486"
] | Ixazomib | Poliovirus type 1 antigen (formaldehyde inactivated) | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a c... | Moderate | 1 | [
[
[
1480,
24,
221
]
],
[
[
1480,
63,
36
],
[
36,
24,
221
]
],
[
[
1480,
64,
581
],
[
581,
24,
221
]
],
[
[
1480,
25,
676
],
[
676,
6... | [
[
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v... | Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Ixazomib may lead to a major life threatening interaction when taken with In... |
DB00539 | DB00619 | 11 | 1,419 | [
"DDInter1837",
"DDInter909"
] | Toremifene | Imatinib | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Moderate | 1 | [
[
[
11,
24,
1419
]
],
[
[
11,
6,
4973
],
[
4973,
45,
1419
]
],
[
[
11,
7,
8924
],
[
8924,
46,
1419
]
],
[
[
11,
18,
5527
],
[
5527,
... | [
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Toremifene",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Toremifene (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Imatinib (Compound)
Toremifene (Compound) upregulates SPAG4 (Gene) and SPAG4 (Gene) is upregulated by Imatinib (Compound)
Toremifene (Compound) downregulates HAT1 (Gene) and HAT1 (Gene) is downregulated by Imatinib (Compound)
Toremifene (Compound) ca... |
DB01156 | DB11640 | 593 | 1,267 | [
"DDInter252",
"DDInter64"
] | Bupropion | Amifampridine | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Amifampridine, or 3,4-diaminopyridine (3,4-DAP), is a quaternary ammonium compound that blocks presynaptic potassium channels, and subsequently prolongs the action potential and increases presynaptic calcium concentrations . It was first discovered in Scotland in the 1970s and its clinical effectiveness for neuromuscul... | Major | 2 | [
[
[
593,
25,
1267
]
],
[
[
593,
25,
1220
],
[
1220,
24,
1267
]
],
[
[
593,
64,
999
],
[
999,
24,
1267
]
],
[
[
593,
25,
913
],
[
913,
... | [
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amifampridine"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
... | Bupropion may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Amifampridine
Bupropion may lead to a major life threatening interaction when taken with Thiethylperazine and Thiethylperazine may ca... |
DB12500 | DB12825 | 283 | 1,375 | [
"DDInter714",
"DDInter1032"
] | Fedratinib | Lefamulin | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Moderate | 1 | [
[
[
283,
24,
1375
]
],
[
[
283,
24,
159
],
[
159,
63,
1375
]
],
[
[
283,
63,
309
],
[
309,
24,
1375
]
],
[
[
283,
64,
1468
],
[
1468,
... | [
[
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
... | Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and ... |
DB00182 | DB06603 | 80 | 39 | [
"DDInter84",
"DDInter1387"
] | Amphetamine | Panobinostat | Amphetamine, a compound discovered over 100 years ago, is one of the more restricted controlled drugs. It was previously used for a large variety of conditions and this changed until this point where its use is highly restricted. Amphetamine, with the chemical formula alpha-methylphenethylamine, was discovered in 1910 ... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Moderate | 1 | [
[
[
80,
24,
39
]
],
[
[
80,
24,
506
],
[
506,
24,
39
]
],
[
[
80,
24,
144
],
[
144,
63,
39
]
],
[
[
80,
40,
1529
],
[
1529,
24,
... | [
[
[
"Amphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Amphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
]... | Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Oloda... |
DB00196 | DB01216 | 600 | 284 | [
"DDInter743",
"DDInter736"
] | Fluconazole | Finasteride | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Finasteride is a synthetic 4-azasteroid compound and specific inhibitor of steroid Type II 5α-reductase, which is an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). It works in a similar fashion as [dutasteride], which is another 5-alpha-reductase inhibitor, by exerting a... | Moderate | 1 | [
[
[
600,
24,
284
]
],
[
[
600,
24,
1260
],
[
1260,
1,
284
]
],
[
[
600,
24,
1561
],
[
1561,
40,
284
]
],
[
[
600,
6,
6799
],
[
6799,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Finasteride"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dutasteride"
],
... | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Dutasteride and Dutasteride (Compound) resembles Finasteride (Compound)
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone (Compound) resembles Finasteride (... |
DB00912 | DB11796 | 473 | 1,612 | [
"DDInter1581",
"DDInter786"
] | Repaglinide | Fostemsavir | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the... | Moderate | 1 | [
[
[
473,
24,
1612
]
],
[
[
473,
63,
1051
],
[
1051,
23,
1612
]
],
[
[
473,
24,
98
],
[
98,
23,
1612
]
],
[
[
473,
24,
1476
],
[
1476,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
]... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Somatr... |
DB00366 | DB11642 | 1,594 | 938 | [
"DDInter600",
"DDInter1480"
] | Doxylamine | Pitolisant | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnag... | Moderate | 1 | [
[
[
1594,
24,
938
]
],
[
[
1594,
24,
1233
],
[
1233,
24,
938
]
],
[
[
1594,
35,
272
],
[
272,
24,
938
]
],
[
[
1594,
63,
475
],
[
475,
... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triprolidine"
],
[
... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine and Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Doxylamine (Compound) resembles Chlorpheniramine (Compound) and Doxylamine may cause a moderate interaction ... |
DB08875 | DB11932 | 1,618 | 327 | [
"DDInter262",
"DDInter3"
] | Cabozantinib | Abametapir (topical) | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Abametapir is a member of bipyridines. | Moderate | 1 | [
[
[
1618,
24,
327
]
],
[
[
1618,
25,
124
],
[
124,
63,
327
]
],
[
[
1618,
24,
283
],
[
283,
63,
327
]
],
[
[
1618,
25,
292
],
[
292,
... | [
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
]
],
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
],
[
"Glasdeg... | Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Cabozantinib may lead to a major life threatening interaction when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Cabozantinib may cause ... |
DB00454 | DB01362 | 1,349 | 497 | [
"DDInter1150",
"DDInter960"
] | Meperidine | Iohexol | A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration. | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
1349,
25,
497
]
],
[
[
1349,
21,
29750
],
[
29750,
60,
497
]
],
[
[
1349,
63,
999
],
[
999,
25,
497
]
],
[
[
1349,
24,
530
],
[
530,
... | [
[
[
"Meperidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Meperidine",
"{u} (Compound) causes {v} (Side Effect)",
"Injection site pain"
],
[
"Injection site pain",
"{u} (Side Effect) is ca... | Meperidine (Compound) causes Injection site pain (Side Effect) and Injection site pain (Side Effect) is caused by Iohexol (Compound)
Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may lead to a major life threatening interaction when take... |
DB00384 | DB00860 | 1,275 | 891 | [
"DDInter1859",
"DDInter1513"
] | Triamterene | Prednisolone | Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension. It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. Since it a... | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Moderate | 1 | [
[
[
1275,
24,
891
]
],
[
[
1275,
24,
175
],
[
175,
40,
891
]
],
[
[
1275,
24,
167
],
[
167,
1,
891
]
],
[
[
1275,
21,
28787
],
[
28787,
... | [
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
... | Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisolone (Compound)
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Pred... |
DB01138 | DB11979 | 804 | 1,320 | [
"DDInter1726",
"DDInter625"
] | Sulfinpyrazone | Elagolix | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
804,
24,
1320
]
],
[
[
804,
62,
168
],
[
168,
23,
1320
]
],
[
[
804,
24,
1297
],
[
1297,
24,
1320
]
],
[
[
804,
63,
79
],
[
79,
... | [
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
... | Sulfinpyrazone may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Os... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.